News

Multiple myeloma patients who received at least three prior lines of therapy and whose cancer expresses the CD33 molecule may enroll in the recently opened…

Janssen Biotech will discuss at a Chicago cancer conference the effectiveness of new multiple myeloma treatment combinations that include its therapy Darzalex (daratumumab). The…

Don Wright, the 76-year-old marathon runner who recently reached his goal of running 100 marathons after being diagnosed with multiple myeloma, ran Philadelphia’s Miles for…

Patients with multiple myeloma soon may be diagnosed and followed solely with the use of a blood sample, avoiding the painful process of collecting a…

The small molecule immunomodulatory drug tasquinimod has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of multiple…

Syrian-born hematologist-oncologist Ahmad Samer Al-Homsi, MD, MBA, will lead an innovative program at NYU Langone’s Perlmutter Cancer Center for treating blood cancers, including multiple…

Amgen submitted a supplemental Biologics Licence Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of Xgeva…

Kite Pharma’s genetically modified T-cell therapy KITE-585 has delayed tumor progression and increased survival in mice with multiple myeloma, according to a preclinical-trial study. The…

Treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD), in addition to a stem cell transplant, improved progression-free survival among multiple myeloma patients…

Poseida Therapeutics‘ P-BCMA-101 eradicates tumors in mouse models of multiple myeloma and creates memory T-cells that go on the attack when the disease returns, preclinical…